Phase 4 Vasculitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with large balloon-like bulges (called giant aneurysms) in one or more of the heart's blood vessels following Kawasaki disease, confirmed by heart ultrasound with specific measurements meeting set thresholds
- Your doctors recommend taking a combination of blood-thinning and anti-clotting medicines for at least the next 6 months
- You are able to take medicines by mouth, or through a feeding tube into the nose or stomach
- You are a child between 1 month and under 18 years of age, and weigh at least 2,600 grams (about 5.7 pounds)
Who may not be able to join:
- You are currently bleeding or have a condition that makes blood-thinning medicines too dangerous to use
- You have a history of blood clots in the veins, or conditions that raise the risk of them, such as certain heart defects, cancer, a central line (large IV), or being unable to move around for long periods
- You have had a serious allergic reaction or other reason you cannot take the medicines being studied
- Your kidneys are not working well enough (confirm with trial site for specific test values)
- Your platelet count (cells that help blood clot) is too low
- You have significant liver disease affecting blood clotting or with certain abnormal liver test results (confirm with trial site for specific values)
- You have high blood pressure that is not being controlled, based on readings above the normal range for your age
- You are currently taking certain strong medicines used for HIV or certain fungal infections that could interfere with the study medicines (confirm with trial site for the specific list)
- You are currently taking certain medicines for infections or seizures that could interfere with the study medicines, including rifampicin, phenobarbital, phenytoin, or carbamazepine
- You are unable or unwilling to follow the study schedule and attend follow-up visits
- You or your guardian are not willing to give consent to participate in the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Fang Liu, MD, Children's Hospital of Fudan University
Phone: 18017590880
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Occurrence of new thrombosis in coronary arteries; Composite of Major bleeding or Clinically relevant non-major bleeding event
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.